Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2017 (2017), Article ID 4347206, 7 pages
https://doi.org/10.1155/2017/4347206
Research Article

Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec

1Quebec University Hospital Research Center, Quebec City, QC, Canada
2Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada
3Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada

Correspondence should be addressed to P. De Wals

Received 17 August 2016; Accepted 4 January 2017; Published 26 January 2017

Academic Editor: Zitta Barrella Harboe

Copyright © 2017 Z. Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. C. Drijkoningen and G. G. U. Rohde, “Pneumococcal infection in adults: burden of disease,” Clinical Microbiology and Infection, vol. 20, supplement 5, pp. 45–51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Moberley, J. Holden, D. P. Tatham, and R. M. Andrews, “Vaccines for preventing pneumococcal infection in adults,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD000422, 2013. View at Google Scholar · View at Scopus
  3. National Advisory Committee on Immunization (NACI), Re-Immunization with Polysaccharide 23-Valent Vaccine (Pneu-P-23), Public Health Agency of Canada, Ontario, Canda, 2015.
  4. È. Dubé, F. Defay, and M. Kiely, Enquête Québécoise sur la Vaccination Contre la Grippe Saisonnière, le Pneumocoque et la Rougeole, Institut National de Santé Publique du Québec, 2013.
  5. È. Dubé, D. Gagnon, and Z. Zhou, Enquête Québécoise sur la Vaccination Contre la Grippe Saisonnière et le Pneumocoque: 2014, Institut National de Santé Publique du Québec, 2015.
  6. National Advisory Committee on Immunization (NACI), Statement on the Use of Conjugate Pneumococcal Vaccine—13 Valent in Adults (Pneu-C-13), Public Health Agency of Canada, 2013.
  7. M. J. M. Bonten, S. M. Huijts, M. Bolkenbaas et al., “Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults,” New England Journal of Medicine, vol. 372, no. 12, pp. 1114–1125, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. K. L. O'Brien, A. B. David, A. Chandran et al., “Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants,” Pediatric Infectious Disease Journal, vol. 27, no. 1, pp. 71–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. T. H. Myint, H. Madhava, P. Balmer et al., “The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review,” Advances in Therapy, vol. 30, no. 2, pp. 127–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. R. Feikin, E. W. Kagucia, J. D. Loo et al., “Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites,” PLoS Medicine, vol. 10, no. 9, Article ID e1001517, 2013. View at Publisher · View at Google Scholar
  11. W. P. Hanage, S. S. Huang, M. Lipsitch et al., “Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptevalent conjugate vaccine era,” Journal of Infectious Diseases, vol. 195, no. 3, pp. 347–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Lefebvre and J. Cote, Programme de Surveillance du Pneumocoque. Rapport 2014, Institut National de Santé Publique du Québec, 2015.
  13. C. G. Whitney, T. Pilishvili, M. M. Farley et al., “Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study,” Lancet, vol. 368, no. 9546, pp. 1495–1502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. A. Waight, N. J. Andrews, S. N. Ladhani, C. L. Sheppard, M. P. Slack, and E. Miller, “Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An Observational Cohort Study,” The Lancet Infectious Diseases, vol. 15, no. 5, pp. 535–543, 2015. View at Publisher · View at Google Scholar
  15. M. R. Moore, R. Link-Gelles, W. Schaffner et al., “Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance,” The Lancet Infectious Diseases, vol. 15, no. 3, pp. 301–309, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. P. De Wals, B. Lefebvre, F. Markowski et al., “Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada,” Vaccine, vol. 32, no. 13, pp. 1501–1506, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Lefebvre, C. Tremblay, P. De Wals et al., Programme de Surveillance du Pneumocoque. Rapport 2013, Institut National de Santé Publique du Québec, Québec, Canada, 2014.
  18. W. P. Hausdorff and W. P. Hanage, “Interim results of an ecological experiment — conjugate vaccination against the pneumococcus and serotype replacement,” Human Vaccines and Immunotherapeutics, vol. 12, no. 2, pp. 358–374, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Hilbe, Modeling Count Data, Cambridge University Press, 2014.
  20. B. F. Manly, “Bootstrapping with models for count data,” Journal of Biopharmaceutical Statistics, vol. 21, no. 6, pp. 1164–1176, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  21. A. J. Van Hoek and E. Miller, “Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England,” PLOS ONE, vol. 11, no. 2, Article ID e0149540, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Tomczyk, N. M. Bennett, C. Stoecker et al., “Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 63, no. 37, pp. 822–825, 2014. View at Google Scholar · View at Scopus
  23. M. Kalin, “Pneumococcal serotypes and their clinical relevance,” Thorax, vol. 53, no. 3, pp. 159–162, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Ahl, N. Littorin, A. Forsgren, I. Odenholt, F. Resman, and K. Riesbeck, “High incidence of septic shock caused by Streptococcus pneumoniae serotype 3—A Retrospective Epidemiological Study,” BMC Infectious Diseases, vol. 13, no. 1, article 492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Hammerschmidt, S. Wolff, A. Hocke, S. Rosseau, E. Müller, and M. Rohde, “Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells,” Infection and Immunity, vol. 73, no. 8, pp. 4653–4667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. N. J. Andrews, P. A. Waight, R. C. George, M. P. E. Slack, and E. Miller, “Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales,” Vaccine, vol. 30, no. 48, pp. 6802–6808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. N. J. Andrews, P. A. Waight, P. Burbidge et al., “Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A Postlicensure Indirect Cohort Study,” The Lancet Infectious Diseases, vol. 14, no. 9, pp. 839–846, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Savulescu, L. Pastore Celentano, G. Hanquet et al., “Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease. Results of SpIDnet2—A European multicentric study (2012–2014). (Poster),” in Proceedings of the 10th International Symposium on Pneumococci and Pneumococcal Diseases, 2016.
  29. M. R. Moore, R. Link-Gelles, W. Schaffner et al., “Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study,” The Lancet Respiratory Medicine, vol. 4, no. 5, pp. 399–406, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Link-Gelles, T. Taylor, and M. R. Moore, “Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020,” Vaccine, vol. 31, no. 22, pp. 2572–2577, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Steens, D. F. Vestrheim, and B. F. de Blasio, “Pneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction study,” Epidemics, vol. 11, pp. 24–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Pilishvili, C. Lexau, M. M. Farley et al., “Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine,” Journal of Infectious Diseases, vol. 201, no. 1, pp. 32–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. H. Choi, M. Jit, S. Flasche, N. Gay, and E. Miller, “Mathematical modelling long-term effects of replacing prevnar7 with prevnar13 on invasive pneumococcal diseases in england and wales,” PLoS ONE, vol. 7, no. 7, Article ID e39927, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. D. M. Weinberger, D. T. Bruden, L. R. Grant et al., “Using pneumococcal carriage data to monitor postvaccination changes in invasive disease,” American Journal of Epidemiology, vol. 178, no. 9, pp. 1488–1495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Douville-Fradet, R. Amini, N. Boulianne et al., Impact du Programme d'Immunisation par le Vaccin Pneumococcique Conjugué Heptavalent (VPC-7) au Québec, Institut National de Santé Publique du Québec, Québec, Canada, 2012.
  36. B. Lefebvre, P. De Wals, G. Deceuninck et al., “Serotype monitoring of streptococcus pneumoniae invasive strains in 5 year olds in the province of quebec: evaluation of a 2 year study,” in Proceedings of the 10th International Symposium on Pneumococci and Pneumococcal Diseases (Poster), 2016.
  37. Z. B. Harboe, T. L. Benfield, P. Valentiner-Branth et al., “Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 329–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. F. Proulx, S. Déry, L. P. Jetté, J. Ismaël, M. Libman, and P. De Wals, “Pneumonia epidemic caused by a virulent strain of Streptococcus pneumoniae serotype 1 in Nunavik, Quebec,” Canada Communicable Disease Report, vol. 28, no. 16, pp. 129–131, 2002. View at Google Scholar · View at Scopus
  39. W. H. B. Demczuk, I. Martin, A. Griffith et al., “Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012,” Canadian Journal of Microbiology, vol. 59, no. 12, pp. 778–788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Rudnick, Z. Liu, A. Shigayeva et al., “Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011,” Vaccine, vol. 31, no. 49, pp. 5863–5871, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. D. Kellner, O. G. Vanderkooi, J. MacDonald, D. L. Church, G. J. Tyrrell, and D. W. Scheifele, “Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the calgary-area Streptococcus pneumoniae research (Casper) study,” Clinical Infectious Diseases, vol. 49, no. 2, pp. 205–212, 2009. View at Publisher · View at Google Scholar · View at Scopus